JP2002537353A5 - - Google Patents

Download PDF

Info

Publication number
JP2002537353A5
JP2002537353A5 JP2000600685A JP2000600685A JP2002537353A5 JP 2002537353 A5 JP2002537353 A5 JP 2002537353A5 JP 2000600685 A JP2000600685 A JP 2000600685A JP 2000600685 A JP2000600685 A JP 2000600685A JP 2002537353 A5 JP2002537353 A5 JP 2002537353A5
Authority
JP
Japan
Prior art keywords
seq
composition
composition according
adjuvant
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000600685A
Other languages
English (en)
Japanese (ja)
Other versions
JP4812942B2 (ja
JP2002537353A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2000/000176 external-priority patent/WO2000050075A2/en
Publication of JP2002537353A publication Critical patent/JP2002537353A/ja
Publication of JP2002537353A5 publication Critical patent/JP2002537353A5/ja
Application granted granted Critical
Publication of JP4812942B2 publication Critical patent/JP4812942B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000600685A 1999-02-26 2000-02-09 ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強 Expired - Fee Related JP4812942B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12179299P 1999-02-26 1999-02-26
US60/121,792 1999-02-26
PCT/IB2000/000176 WO2000050075A2 (en) 1999-02-26 2000-02-09 Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010114804A Division JP2010174044A (ja) 1999-02-26 2010-05-18 ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強

Publications (3)

Publication Number Publication Date
JP2002537353A JP2002537353A (ja) 2002-11-05
JP2002537353A5 true JP2002537353A5 (https=) 2007-03-29
JP4812942B2 JP4812942B2 (ja) 2011-11-09

Family

ID=22398817

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000600685A Expired - Fee Related JP4812942B2 (ja) 1999-02-26 2000-02-09 ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
JP2010114804A Withdrawn JP2010174044A (ja) 1999-02-26 2010-05-18 ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010114804A Withdrawn JP2010174044A (ja) 1999-02-26 2010-05-18 ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強

Country Status (11)

Country Link
US (1) US8221761B1 (https=)
EP (1) EP1154790B1 (https=)
JP (2) JP4812942B2 (https=)
AT (1) ATE279943T1 (https=)
AU (1) AU2457100A (https=)
CA (1) CA2371994C (https=)
DE (1) DE60015084T2 (https=)
ES (1) ES2228454T3 (https=)
HK (1) HK1042425B (https=)
PT (1) PT1154790E (https=)
WO (1) WO2000050075A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
NZ515935A (en) * 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
BR0015961A (pt) 1999-11-29 2003-06-10 Chiron Spa Antìgeno de neisseria de 85kda
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
EP1379272B1 (en) * 2001-04-17 2010-01-20 Novartis Vaccines and Diagnostics, Inc. Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
EP1438323A4 (en) * 2001-10-03 2007-08-01 Novartis Vaccines & Diagnostic ADJUVOUS MENINGOCOCCUS COMPOSITIONS
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
US20050238660A1 (en) * 2001-10-06 2005-10-27 Babiuk Lorne A Cpg formulations and related methods
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) * 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1047784B2 (en) * 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261338A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9820003D0 (en) * 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
EP1144643A1 (en) * 1999-01-15 2001-10-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. Neisseria meningitidis antigen
EP1149164A2 (en) * 1999-01-22 2001-10-31 SmithKline Beecham Biologics SA Neisseria meningitidis polypeptides
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
WO2000066741A2 (en) * 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
US7767197B2 (en) * 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
US20040258702A1 (en) * 2000-06-22 2004-12-23 Blonder Joan P. Vaccine delivery
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
MXPA03002643A (es) * 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
EP1379272B1 (en) * 2001-04-17 2010-01-20 Novartis Vaccines and Diagnostics, Inc. Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
US6541554B2 (en) * 2001-05-17 2003-04-01 Milliken & Company Low-shrink polypropylene fibers
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
EP2263687B1 (en) * 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
BRPI0410423A (pt) * 2003-05-07 2006-06-06 Sanofi Pasteur Inc processo de imunogenicidade melhorada para vacinação meningocócica
US20060182793A1 (en) * 2003-07-22 2006-08-17 Cytos Biotechnology Ag Cpg-packaged liposomes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
GB0401239D0 (en) * 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
KR100721928B1 (ko) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
SI1858920T1 (sl) * 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
AR054020A1 (es) * 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
EA015817B1 (ru) * 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
US20090089165A1 (en) * 2007-09-28 2009-04-02 Embarq Holdings Company, Llc System and method for a telephony upgrade credit

Similar Documents

Publication Publication Date Title
JP2002537353A5 (https=)
CA2371994A1 (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
Cunningham et al. Vaccine development: From concept to early clinical testing
McCluskie et al. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
Reed et al. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants
JP5148577B2 (ja) 非毒性の粘膜アジュバント
Singh et al. Advances in vaccine adjuvants
Ioannou et al. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein
Vajdy et al. Microparticles for intranasal immunization
Czerkinsky et al. Mucosal immunity and tolerance: relevance to vaccine development
Kwant et al. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2
Hamasur et al. Mycobacterium tuberculosis arabinomannan–protein conjugates protect against tuberculosis
Chen Recent advances in mucosal vaccine development
AU749282B2 (en) Immunostimulant emulsion
McCluskie et al. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants
Vordermeier et al. Effective DNA vaccination of cattle with the mycobacterial antigens MPB83 and MPB70 does not compromise the specificity of the comparative intradermal tuberculin skin test
CN103025351A (zh) 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
WO2022228560A1 (zh) 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
Russell et al. Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases—a review
EP2359850A1 (en) Single-time vaccines
Chin et al. Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants
Igietseme et al. Delivery of Chlamydia vaccines
JP2023517330A (ja) 破傷風、ジフテリア、および百日咳に対する能動的追加免疫付与
EP1924279A2 (en) Adjuvanted vaccine